Speaking at an investor day late last week, Novartis chief financial officer Harry Kirsch outlined how the company plans to generate "substantial savings" by working with external data management vendors.
While the recent hack of FDA databases raised plenty of questions about its cybersecurity policies, the agency offered few answers. If a damning new report into government-wide practices is in any way representative of the FDA though, the agency will need to tighten up.
In the 20 months since the White House unveiled its $200 million Big Data R&D initiative, the field has matured and begun to fulfill its potential. Now the government has inked a batch of data-related projects and signed up Eli Lilly, Novartis and Pfizer as partners.
With payers in key markets pushing for lower drug prices and generics slaying many of Big Pharma's cash cows, one way companies are trying to achieve efficiency goals is through increased spending on business intelligence and analytics tools.
It is now two months since Google sparked speculation by unveiling vague but ambitious plans to enter the biotech sector. Details of what the spinout, called Calico, will do are still limited, but we now know some of the people who will run the show. Unsurprisingly, Google has poached some heavy hitters.
Frost & Sullivan predicts the falling cost of next-generation sequencing will cause the informatics market to triple in value by 2018.
BlackBerry phones are a defining tech of the first decade of the 21st Century, a time when suited Big Pharma execs used the devices to facilitate multi-billion dollar takeovers. At Pfizer, the mega-merger era it helped create is over, and now its relationship with BlackBerry is coming to a close, too.
Rising use of Fitbit wristbands, Withings scales and other self-tracking devices mean individuals have access to a pool of personal health data that in some respects far exceeds what clinical trials gather. Now, Validic has secured funding from Dallas Mavericks-owner Mark Cuban to bring the devices into healthcare.
When Pfizer came to set up its Twitter account in 2009, the social network was already a big deal, with users sending 100,000 tweets per hour when Michael Jackson died. Arriving late to the party meant the @Pfizer handle was already taken. Now, four years later, Pfizer has finally claimed the account.
When the European Medicines Agency released its draft policy on clinical trial data disclosure in June, it expected a big response. And it got one, with more than 1,000 comments submitted in the four-month consultation period. Working through this feedback is taking a little longer than expected, though.
In the flurry of chatter about the implications of last month's government shutdown, cybersecurity experts tried to get one point across--the furloughing of staff makes us vulnerable. With fewer staff guarding the U.S., the fear was hackers would strike. Now, the experience of FDA shows fears were well founded.
Veeva Systems CEO Peter Gassner spoke to Forbes about the company and its plans to expand its products.
Life science vendors face a balancing act when using social media. Giving users the hard sell will bring rejection and reflect badly on the company, but a softly-softly plan might not be noticed at all. Fortunately for vendors, a survey suggests scientists are increasingly accepting of companies on Facebook and Twitter.
Open and closed systems have divided the tech sector for years, with people taking deeply entrenched positions in Apple versus Android and Linux versus Windows debates. And when this philosophical split is applied to genomics, the stakes ratchet up significantly, as the U.K. found this week.
With researchers estimating that as many as 70% of new chemical entities (NCEs) are poorly soluble in water, service providers have scrambled to offer drug delivery technologies that improve bioavailability. But which is right for your active ingredient? Catalent has created software to help answer this question.
Open-source software developers have long stood on the shoulders of giants, incorporating existing tools where possible so they can focus resources on improving other areas. And with the proliferation of open-source genomics programs, Biodatomics is betting on the model working for bioinformatics.
The reauthorization of PDUFA committed the FDA to giving patients a stronger voice in regulatory decisions, particularly when assessing the benefits and risks of new drugs. The FDA is planning a series of meetings, and Genetic Alliance thinks it's found a way to accelerate the gathering of patient feedback--crowdsourcing.
Over the past year, the "digital" development model pioneered by NuMedii has begun to deliver, with a Phase IIa trial of a computationally found drug-disease match now underway. The next clinical candidates are in databases awaiting discovery, and this week NuMedii inked a deal to increase its chances of finding them.
GoBalto has introduced version 2.0 of Tracker, its software-as-a-service platform designed to streamline clinical trial startup.
The software is the result of a three-year effort by Rhenovia and its collaborators to develop a computer model for epilepsy that is validated by laboratory experiments. Having created the software, Rhenovia is looking to market it to biopharma companies. The platform could help identify new therapeutic candidates--or reposition existing molecules--and assess their toxicology and safety profiles.